0000902664-17-002229.txt : 20170508
0000902664-17-002229.hdr.sgml : 20170508
20170508185658
ACCESSION NUMBER: 0000902664-17-002229
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170504
FILED AS OF DATE: 20170508
DATE AS OF CHANGE: 20170508
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: venBio Select Advisor LLC
CENTRAL INDEX KEY: 0001633313
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 17823952
BUSINESS ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: SUITE 2802
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 212-937-4975
MAIL ADDRESS:
STREET 1: 120 WEST 45TH STREET
STREET 2: SUITE 2802
CITY: NEW YORK
STATE: NY
ZIP: 10036
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Aghazadeh Behzad
CENTRAL INDEX KEY: 0001701815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 17823953
MAIL ADDRESS:
STREET 1: C/O VENBIO SELECT ADVISOR LLC
STREET 2: 120 W. 45TH STREET, 28TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
4
1
p17-1181form4.xml
BEHZAD AGHAZADEH
X0306
4
2017-05-04
0
0000722830
IMMUNOMEDICS INC
IMMU
0001701815
Aghazadeh Behzad
C/O VENBIO SELECT ADVISOR LLC
120 W. 45TH STREET, 28TH FLOOR
NEW YORK
NY
10036
1
0
0
1
See Remarrks
0001633313
venBio Select Advisor LLC
120 WEST 45TH STREET
SUITE 2802
NEW YORK
NY
10036
1
0
0
0
Series A-1 Convertible Preferred Stock, par value $0.01
5.41
2017-05-04
4
A
0
184000
125.00
A
Common Stock, par value $0.01 per share ("Common Stock")
4251386
184000
I
See footnotes
These shares of Series A-1 Convertible Preferred Stock are automatically convertible into shares of common stock, par value $0.01 per share (the "Common Stock") upon approval by the Issuer's stockholders to increase the number of the Issuer's authorized shares of Common Stock to enable conversion of all outstanding shares of Series A-1 Convertible Preferred Stock. As of the date hereof, approval by stockholders of the Issuer has not been obtained and, accordingly, the Series A-1 Convertible Preferred Stock is not currently convertible.
The securities reported herein are held on behalf of accounts managed by venBio Select Advisor LLC, a Delaware limited liability company (the "Investment Manager") and venBio Select Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
The Investment Manager may be deemed to be a director by deputization of Immunomedics, Inc. (the "Issuer") by virtue of the fact that Dr. Agahazadeh currently serves on the board of directors of the Issuer.
venBio Select Advisor LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
2017-05-08
/s/ Behzad Aghazadeh
2017-05-08